Our patients
are at the core
of what we do.

We’d like to express our appreciation for the patients who have previously participated or are currently enrolled in our clinical trials. Your contributions will help others as a result of the knowledge gained from your participation.

Our Clinical Trials

We’re actively recruiting patients to participate in clinical trials to evaluate our therapeutic candidates. If you believe you might be a good candidate, we encourage you to reach out directly via the link below.


Cardiac Surgery

RBT-1 (stannic protoporfin/iron sucrose) is a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and or valve surgery. RBT-1 has started its Phase 3 registrational study to reduce the risk of post operative complications and improve outcomes cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations.

RBT-1 Pivotal
Phase 3 Study

Now Enrolling

Advocacy Research Partnerships

Reach Out
to Learn More